Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway
- PMID: 11388794
- DOI: 10.1006/prep.2001.1417
Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway
Abstract
The development of recombinant techniques for rapid cloning, expression, and characterization of cDNAs encoding antibody (Ab) subunits has revolutionized the field of antibody engineering. By fusion to heterologous protein domains, chain shuffling, or inclusion of self-assembly motifs, novel molecules such as bispecific Abs can be generated that possess the subset of functional properties designed to fit the intended application. We describe the engineering of Ab fragments produced in bacteria for blocking the CD28-CD80/CD86 costimulatory interaction in order to induce tolerance against transplanted organs. We designed single-chain Fv antibodies, monospecific and bispecific diabodies, and a bispecific tetravalent antibody (BiTAb) molecule directed against the CD80 and/or CD86 costimulatory molecules. These recombinant Ab molecules were expressed in Escherichia coli, followed by purification and evaluation for specific interaction with their respective antigen in an enzyme-linked immunosorbent assay (ELISA). A specific sandwich ELISA confirmed the bispecificity of the bispecific diabodies and the BiTAb.
Copyright 2001 Academic Press.
Similar articles
-
A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.J Mol Biol. 2005 Mar 11;346(5):1299-311. doi: 10.1016/j.jmb.2004.12.052. Epub 2005 Jan 22. J Mol Biol. 2005. PMID: 15713482
-
Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains.J Mol Biol. 2001 Jul 13;310(3):591-601. doi: 10.1006/jmbi.2001.4703. J Mol Biol. 2001. PMID: 11439026
-
Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting.Clin Cancer Res. 2000 Nov;6(11):4314-22. Clin Cancer Res. 2000. PMID: 11106249
-
Engineered antibodies.Nat Med. 2003 Jan;9(1):129-34. doi: 10.1038/nm0103-129. Nat Med. 2003. PMID: 12514726 Review. No abstract available.
-
[Bispecific antibodies: what future?].Med Sci (Paris). 2009 Dec;25(12):1155-8. doi: 10.1051/medsci/200925121155. Med Sci (Paris). 2009. PMID: 20035697 Review. French.
Cited by
-
Construction and expression of D-dimer and GPIIb/IIIa single-chain bispecific antibody.Exp Ther Med. 2013 Aug;6(2):552-556. doi: 10.3892/etm.2013.1132. Epub 2013 May 30. Exp Ther Med. 2013. PMID: 24137225 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources